Semaglutide is a GLP-1 receptor agonist medication that may be considered for certain patients as part of a physician-supervised weight-management plan
JAMA Network Open (August 12, 2025) reports higher risk of nonarteritic anterior ischemic optic neuropathy across ~1.5M patients, and a separate analysis in ~185k found a modest uptick in diabetic retinopathywhile sight-threatening events were less frequent on GLP-1s
MitraSPaulSRoySSutradharHBin EmranTNainuFet al
With regular use, after all, you will experience a more uniform and radiant skin tone
Therefore, if you notice serious weight gain after starting a new prescription drug, speak to your doctor to see if this may be one of the side effects
Antibody production The GDF8 mAb (trevogrumab, also known as REGN1033) was generated using VelocImmune HumAb mouse 28,29 and developed as published 14,30